Aytu BioPharma, Inc. (AYTU) AI Stock Analysis

Aytu BioPharma, Inc., headquartered in Englewood, Colorado, commercializes innovative therapeutics and consumer healthcare products in the United States and globally. Its portfolio includes ADHD treatments Adzenys XR-ODT and Cotempla XR-ODT for patients aged six and older. The company also markets Karbinal ER, an oral suspension for seasonal and perennial allergy symptoms, along with Poly-Vi-Flor and Tri-Vi-Flor prescription fluoride supplements for pediatric nutrition. Founded in 2015 and rebranded from Aytu BioScience, Inc. in March 2021, Aytu operates with 75 employees across pharmaceutical development and commercialization.

Aytu BioPharma's revenue reached $57.6M in FY2026, dropping 13.3% from $66.4M in FY2025 and down from peak annual revenue of $107.4M in FY2023. Five-year revenue CAGR from FY2021 to FY2026 stands at -2.6%. Gross margin was 64.0% in FY2026, down from 69.0% in FY2025 and 75.3% in FY2024. Operating margin for FY2026 was -14.4%, resulting in a net loss of -$14.3M and an EPS of -$0.78. For the latest quarter ended June 30, 2026, quarterly revenue growth improved by 6.4% year-over-year, while TTM profit margin registered at -24.8%.

As of June 30, 2026, Aytu BioPharma held $26.3M in cash and short-term investments against total debt of $18.1M, creating a net cash balance of $8.2M. Shareholders' equity was $35.3M out of $105.0M in total assets, with a current ratio of 1.13 and a debt-to-equity ratio of 0.51. In FY2026, operating cash flow and free cash flow both turned positive at $3.3M, aided by minimal capital expenditures of $29,000. Over five years, the company's share count increased by 833.2%.

Aytu BioPharma trades at an enterprise value of $15.6M and a price-to-sales multiple of 0.4x, below the 4.1x median of its US-listed Healthcare peers. Its EV/EBITDA multiple of 1.1x is also lower than the peer median of 12.0x, while its forward P/E stands at 9.2x compared to the peer median of 17.3x. AYTU closed at $2.04 on October 16, 2026, down 12.1% over the past year and down 96.2% over five years, underperforming the S&P 500 (SPY) gains of 16.8% and 83.0% over the same periods.

Wall Street coverage includes 3 analysts, with 2 Strong Buy ratings and 1 Buy rating. The mean price target is $9.67, representing a 373.9% premium over the last close of $2.04. For the current fiscal year ending June 30, 2027, consensus estimates project revenue of $67.9M and an EPS of -$0.36, reflecting an EPS growth estimate of 56.0%. Two analysts project FY2028 revenue to reach $86.9M with EPS turning positive to $0.15. The company beat EPS estimates in each of the last 4 quarters, and its next earnings date is November 12, 2026.

This page is an AI-written research summary of Aytu BioPharma, Inc. (AYTU). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.

Related: AYTU income statement, AYTU balance sheet, AYTU key metrics, AYTU analyst forecast, AYTU chart. See the AYTU stock overview for the latest quote and news.